BTC 
ETH 
BNB 
XRP 
SOL 
TRX AbbVie beats Q3 forecasts on Skyrizi strength; stock slips
Investor's Business Daily reported that AbbVie easily beat third-quarter forecasts, helped by its biggest drug, Skyrizi, and that its earnings doubled. The same post said AbbVie stock slipped slightly on Friday.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
What the sources claim
-
AbbVie easily beat third-quarter forecasts, helped by its biggest drug Skyrizi.
“the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi”
Investor's Business Daily -
AbbVie's earnings doubled.
“AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again”
Investor's Business Daily -
AbbVie stock slipped slightly on Friday.
“AbbVie stock slipped slightly Friday”
Investor's Business Daily
Sources
More in Stocks & Indices
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-30 13:00 UTC. Labels are computed from the sources, not by the model.